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http://www.jnanobiotechnology.com/content/12/1/10RESEARCH Open AccessThymosin β4 coated nanofiber scaffolds for the
repair of damaged cardiac tissue
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After a cardiac event, proper treatment and care of the damaged tissue is crucial in restoring optimal cardiac
function and preventing future cardiac events. Recently, thymosin β4 has been found to play a vital role in
cardiac cell health and development by regulating angiogenesis, inflammatory responses, and wound healing.
We proposed that defined poly(ε-caprolactone) (PCL) nanoscaffolds coated with thymosin β4 could efficiently
differentiate murine-derived cardiomyocytes into functioning cardiac tissue. PCL nanoscaffolds were developed
through electrospinning technology, and subsequently coated with a thymosin β4 solution. Cardiomyocytes were
seeded on coated and uncoated nanoscaffolds and observed for six days via fluorescent and electron microscopy.
Our results demonstrated a robust growth and differentiation of cardiomyocytes on coated nanoscaffolds compared
with uncoated, showing potential for nanoscaffold-mediated cardiac cell replacement in vivo after an MI or other
cardiac event.
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Cardiac cell health post-myocardial infarction is impera-
tive in the proper future functioning of the heart [1,2].
After MI, formation of fibrotic scar issue impairs the
ability of the heart to properly function, leading to higher
risk for a second cardiac event [3,4]. Developing new me-
thods to treat these disease events is imperative. Literature
has shown that the 43-amino acid protein thymosin β4
(Tβ4) acts by sequestering G-actin monomers, subse-
quently effecting actin-cytoskeletal organization necessary
for cardiac cell motility, organogenesis, and other crucial
cellular events necessary for repair [5].
The correlation between Tβ4 and cardiac cells has been
of great interest and debate worldwide [6], but the over-
whelming majority of studies have pointed to Tβ4 having
a positive effect. Using epicardium derived progenitor cells
(EPDCs), Gajzer et al. [7] and Smart, et al. [8] have shown
in vivo that EPDCs primed with Tβ4 differentiate into car-
diomyocytes, and can be used to repair the myocardium
after ischemic damage. Downregulation of Tβ4 using
a blocking antibody was shown to decrease survival of* Correspondence: arunk@udel.edu
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reversed by exogenous addition of Tβ4 [9]. It has been
widely demonstrated that Tβ4 can promote cardiac cell
migration [5,10,11], activate proliferation of cardiac fibro-
blasts and endothelial cells [5,7-9,12], and promote neoan-
giogenesis (development and formation of blood vessels)
[5,10,11,13]. It has also been shown in rodent and pig
models of myocardial infarctions that Tβ4 has potent
effects in limiting the amount of damage caused by coron-
ary ligation and, more recently, Tβ4 administration before
injury appeared to prime a population of epicardium-
derived progenitor cells to become new cardiomyocytes
[10].
Besides the use of Tβ4, there have been various tech-
niques employed to regrow and differentiate cardiomyo-
cytes (for a comprehensive review of the methodology,
see Ref. 9 and 12). Our focus will be on the applications
of a polymer-based nanofiber scaffold to be used as a
platform for animal cell growth and differentiation. For
biomedical applications these nanoscaffolds are made of
naturally occurring, biocompatible materials such as col-
lagen, starch, poly(L-lactide) and poly(ε-caprolactone)
(PCL), or any combination thereof [14] that will slowly
and consistently dissolve in vivo. This dissolving can be
used to deliver such things as therapeutic drugs [15] orLtd. This is an Open Access article distributed under the terms of the Creative
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by various methods, including phase-separation, self-
assembly, or electrospinning [17], each having benefits
and detriments depending on the application.
Here, we aimed to use the beneficial properties of PCL
to develop a scaffold for the growth and differentiation
of cardiomyocytes derived from rat cardiac tissue. The
goal was to develop a structurally sound scaffold coated
with Tβ4 that would successfully propagate cells ex vivo
for future in vivo cardiac tissue repair applications.
Methods
PCL solution formulation
PCL tablets were purchased from Sigma Aldrich (CAS
24980; St. Louis, MO). Dichloromethane (DCM) and N,
N-dimethylformamide (DMF) were purchased from Acros
Organics (Geel, Belgium). PCL tablets weighing 1.5 g were
dissolved in a solvent mixture containing a 1:4 ratio of
DCM to DMF. This combination was sonicated for 1 hour
to ensure tablets were fully dissolved.
Electrospinning of nanoscaffold
1.5 mL PCL/DMF/DCM solution was suctioned into a
syringe and attached to a flow rate controller (Thermo
Scientific, Waltham, MA). The solution was pumped at
a flow rate of 0.5 mL/h. A Voltmeter lead was attached
to the syringe needle and the other lead was attached to
a rolling drum that housed an aluminum sheet (Oriental
Motor, Tokyo, Japan). The rolling drum was mounted
on an E7 Limo easy linear motion controller (Oriental
Motor) for linear and rotational fiber distribution. The
Human Machine Interface (Omron, Kyoto, Japan) was
set at a 3 hr run time, a starting position of the E7 Limo
at 105 mm, and a rolling drum speed of 630RPM. A po-
tential of 12 kV was applied between the spinneret and
grounded collector located 12 cm below the spinneret
to pull the solution from the syringe and accurately line
the fibers to the rolling drum mounted on the E7 Limo.
IR nanoscaffold characterization
A Nicolet iS5 spectrometer with an iD1 Transmission
adapter (Thermo Scientific, Waltham, MA) was used to
perform Fourier transformed infrared spectroscopy
(FTIR). The fibers were measured to determine charac-
teristic peaks relating to bond stretching and rocking,
using air as a blank. The FTIR analysis was carried
out over a wave number range between 4000 and
400 cm−1 at a resolution of 2 cm−1.
Microscopic nanoscaffold characterization
Scanning electron microscopy (SEM) was performed to
visualize the initial fibers. Fibers were mounted on alu-
minum mount-M4 sample holders (Electron Microscopy
Sciences, Hatfield, PA) and placed in a Denton Bench TopTurbo III vaccum chamber (Denton Vacuum, Moorestown,
NJ) for coating with a 50:50 mix Au:Pd to aid visua-
lization. The samples were placed into the SEM (Hitachi
S4700, Hitachi High Technologies, Tokyo, Japan) and im-
ages were taken from 1000× to 5000× to ensure linearity
and even size.
Transmission electron microscopy was performed on
Day 4 of treated cell culture to ensure even cell distribu-
tion and proliferation through the fiber scaffold. Cell and
fiber suspensions were cryogenically prepared and moun-
ted into the Libra 120 Transmission Electron Microscope
(Carl Zeiss, Inc., Thornwood, NY).
An EvosFL Cell Imaging System (Life Technologies,
Carlsbad, CA) was used to monitor cell growth and de-
termine cell counts. Cells were washed and placed on the
microscope stage. An image was taken, and the Toolbar
function was used to place a hemocyometer grid on the
screen for cell counts.Nanoscaffold preparation
Nanofiber scaffolds were transferred into petri dishes,
sterilized with 70% ethanol for several hours, rinsed with
phosphate buffered saline (PBS), and coated with 0.1%
polylysine aqueous solution for 4 to 6 h prior to cell
seeding. Treated scaffolds were coated with thymosin
β4 solutions at concentrations of 0.5-7.5% w/v. Prior
to seeding but following coating, scaffolds were rinsed
with Ultrapure water (Millipore) to remove any excess
thymosin β4 residue not sticking to the scaffold.Cell culture
Cells were extracted as described in [18], in which colla-
genase digestion of murine left ventricles was followed
by centrifugal separation. Cultures were prepared in
Cardiomyocyte Differentiation Medium (StemCell
Technologies) and seeded on two scaffolds: One on a
nanofiber scaffold treated with a thymosin β4 coating; the
other was prepared on an uncoated scaffold for compari-
son. Stem cells were seeded at a concentration of 1×106
over both scaffolds and allowed to grow in a cultured
medium. Cells were incubated in a Forma Steri-Cycle
CO2 Incubator (Thermo Scientific, Waltham, MA) at
36.5°C and 3.0% CO2. Cardiomyocytes were characterized
based on control and antibody staining as described in the
Cardiomyocyte Characterization Kit protocol (Millipore).Statistics
The statistical significance of the results was determined
using analysis of variance (ANOVA) and a multiple means
comparison function (t-test) in JMP with an alpha level of
0.05. All error bars are reported in mean ± standard error
from the mean, with n = 5 unless otherwise noted.
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Microscopic examination
Scanning electron micrograph (SEM) images and Evos
FL images were taken to ensure parallel nanoscaffold
fiber assembly (Figure 1). Nanoscaffolds were peeled dir-
ectly from the foil wrapper of the rolling drum and placed
on a microscope slide, sans cover slip, and placed on the
deck of the Evos instrument for imaging (Figure 1a). For
SEM images, after peeling from the foil the nanoscaf-
fold was gently pulled apart to tease out individual fiber
bundles that were still connected to the whole scaffold
(Figure 1b). These individual fiber bundles were prepared
as described in Methods. We found that our electrospun
PCL nanoscaffolds held a generally linear nature via the
Evos and they maintained this property even on the
fringes of the nanoscaffold as seen through SEM. The
bundles of fibers were approximately 2 μm wide and
comprised of 4 to 8 individual fibers, with each indivi-
dual fiber measuring 400 ± 100 nm. Nonlinear or clumped
samples were discarded prior to culturing.Figure 1 Representative images from electrospun nanofiber
scaffolds. (a) Evos FL and (b) scanning electron microscope images
of the nanoscaffold fibers before coating. Increased linearity and
porosity is directly correlated to improved cell adherence and
growth [20]. Scale bar in (a) 200 μm, in (b) 20 μm.FTIR characterization
PCL has a relatively long hydrocarbon chain in the re-
peating unit [−(CH2)5-] before ending in an ester linkage
[−R1–CO–O–R2-] to the next repeat (Figure 2a). Using
the iD1 Transmission adapter for the FTIR, we sought to
determine the composition of the noncoated (Figure 2b)
and coated (Figure 2c) nanoscaffold based on bond
stretching and peak appearances. Characteristic PCL ester
stretching from the C =O occurred at 1260 cm−1, and the
carbonyl structure can be seen strongly at 1730 cm−1. A
peak at 2980 cm−1 and the accompanying shoulder at
2950 cm−1 are indicative of extensive C-H bonding. The
coated nanoscaffold contained the key PCL characteristics
as expected. Also, as noted in the figure, amine (3500-
3300 cm−1) and aromatic (860-680 cm−1) moieties ap-
peared when the nanoscaffold was coated, indicative of
the notable amino acid structures within Tβ4.
Coating of nanofiber
It was necessary to determine the optimal concentra-
tions of Tβ4 to use for practicality and to ensure biolo-
gical compatibility. Concentrations from 0% to 7.5% Tβ4
w/v were used for nanoscaffold coating. Coating with
Tβ4 rendered the nanoscaffolds autofluorescent, eliminat-
ing the need for chemiluminescent or staining procedures
(Figure 3a&b). The 0.5% solution did not significantly
differentiate cardiomyocytes while the 1% and 1.5% Tβ4 so-
lutions significantly increased cell proliferation and differ-
entiation (Figure 3). Both 1% and 1.5% gave the same
relative data, so we chose to move forward with the 1% so-
lution for cost and procedural efficiency (Figure 3c-e). Our
coating experiments produced a parabolic data set, where
lower concentrations expectedly led to lower cell counts,
but higher concentrations also led to lower cell counts.
Cell seeding
After the nanoscaffold was coated, it was laid flat in a separ-
ate, sterile petri dish and smoothed flush to the edges to en-
sure full cell coverage. Control, uncoated nanoscaffolds
were also laid out the same way in separate dishes. Cells
were seeded to each scaffold at 1×106 cells/mL. Monitoring
via Evos transmittance and DAPI filter settings showed no
cell loss due to culture transfer after 2 days (Figure 4a&d).
Cell propagation on coated nanoscaffolds
Cells were diluted 1:5000 for accurate counting purposes
and observed for 6 days (Figure 4a-f). Cardiomyocyte
Characterization Kit (Millipore) was used throughout to en-
sure cell propagation was in fact a cardiomyocyte culture,
and not contaminant cell types. Day 0 showed viable cell
populations not statistically significant from uncoated con-
trol to Tβ4 coated nanoscaffolds. By Day 2 there was already
a significant difference between the cardiomyocytes grown
on coated nanoscaffolds compared to uncoated nanoscaffold
Figure 2 Fourier Transformed Infrared spectroscopy output of the PCL nanofiber scaffold. (a) The repeating monomer that makes up poly
(ε-caprolactone). (b) FTIR iD1 transmission output of a scanned pure PCL scaffold. Peaks of particular interest are highlighted. (c) Output of a
scanned PCL scaffold coated with thymosin B4. Notice highlighted differences where proteinaceous material stands out from the pure PCL graph.
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(Figure 5a&c). Day 4 coated nanoscaffolds with cells were
imaged with cryo-TEM to ensure proper growth and seed-
ing (Figure 4g). Day 6 demonstrated continued differenti-
ation of the cardiomyocytes grown on the treated scaffold,
with the largest decline in the cells cultured on the uncoated
control nanoscaffold (p = .007) (Figure 5a&d). Overall, these
final day results represent a 122% increase in cardiomyocyte
number for treated cells, and a decrease of 19% in uncoated
control cells from initial seeding concentrations (Figure 5d).
Discussion
Our work was performed with the goal of determining
the effect of a new and novel coating on a nanoscaffoldto be used in repairing cardiac muscle after damaging
cardiovascular events. After fabrication any nanoscaffold
construct can be subjected to coating, allowing the fiber
to display novel researcher-selected properties such as
hydrophobicity, bioactivity, or fluorescence [18]. The bio-
active coatings can significantly enhance cell growth, cell
signaling, and in vivo biocompatibility [19].
Based on previous literature findings, thymosin β4 was
chosen as a coating for the scaffolds to propagate and
differentiate cardiomyocytes derived from mice to de-
velop an ex vivo growth system. To our knowledge, this
is the first time PCL nanofiber scaffolds were coated
with a thymosin β4 solution and used for successful
growth and preparation of cardiomyocytes in an ex vivo
Figure 3 Representative images from coated and uncoated scaffolds. (a) 40× bright field image of uncoated scaffold and (b) fluorescent image
of thymosin β4 coated scaffold. Thymosin β4 autofluoresces and can therefore be seen without use of GFP or fluorescein. Notice thickness change increase
from uncoated to coated scaffold fibers. Scale bar: 100 μm. Images of cells on coated fibers at (c) 0.5%, (d) 1%, and (e) 1.5% thymosin β4. Significances in cell
count are noted. *p < 0.05 by t-test n = 5; ns: no significance. Nanoscaffolds are labeled with blue arrowheads; cell bundles with red arrowheads.
Figure 4 Cell images at different stages of growth. Control cells at (a) Day 2, (b) Day 4, and (c) Day 6 of growth. Notice the extensive fiber
concentration but depleted cell content as early as Day 2. Treated cells (d) Day 2 and (e) Day 4 are significantly more populated with differentiated
cardiomyocytes when compared with controls (p < 0.05 by t-test, n = 5). (f) Day 6 cells show even more extensive cardiomyocyte growth aided by
the thick scaffold underlay (p < .01 by t-test, n = 5). (g) Transmission electron microscope images of treated cells were taken at Day 4. Notice cell
infiltration, adhesion, and active division. Scale bar 30 μm. Nanoscaffolds are labeled with blue arrowheads; cell bundles with red arrowheads.
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Figure 5 Differences in cell counts on coated vs uncoated nanoscaffolds over time. (a) Percentage change in cell growth over the
observation period on Tβ4 coated vs uncoated scaffolds. (b) Comparison of increases in the percentage of cell growth over the observation period
within the coated samples. (c) Fold changes of cell growth comparing Tβ4 coated vs uncoated through the first 4 days of observation. (d) Comparison
of Tβ4 coated vs uncoated scaffolds on the final day of observation Day 6 separated to show significance. All values are averages of 5 replicate counts
of each scaffold growth condition. Asterisks represent differences between treated and control for a given day, *p < 0.05, **p < 0.01 by t-test, n = 5.
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coating presumably allowed a positive combinatorial ef-
fect with the PCL electrospun nanoscaffolds. This effect
was stunted with an overwhelming proportion of Tβ4
greater than 2% (data not shown), and is comparable to
previously described in vitro data where an overwhelm-
ing proportion of Tβ4 caused uncontrolled disassocia-
tions of actin bundles [20]. We therefore propose the
use of lower and therefore less costly concentrations of
Tβ4 could be efficiently used for cell differentiation.
Poly(ε-caprolactone) (PCL) has advantageous chemical
properties that lends itself to biological applications. PCL
is a biodegradable polymer with a slow rate of degradation
[21] and low toxicity [22]. It also shows high anisotropy in
cardiomyocyte cell culture when produced through elec-
trospinning methods, and, despite being a soft and flexible
material PCL fibers are able to withstand the contraction
force of a beating heart [21]. PCL nanofiber scaffolds pro-
vided a sturdy platform for ex vivo cell growth and are a
strong, biocompatible, and flexible delivery system of cells
to an in vivo system.
Throughout this study five replicate PCL fiber solu-
tions electrospun for three hours on to tin foil-coated
rolling drums were analyzed using multiple microscopic
techniques to ensure the desired topographical features
of linearity and porosity were achieved. Electrospinningallows nanoscaffolds produced to have extremely small di-
ameters, creating a high surface area to volume ratio on
which the cells can attach and proliferate [5]. Electrospun
fibers also have topographical features that encourage cell
adhesion, growth, and differentiation [23]. Our early mi-
croscopic analysis was performed to insure the nanos-
caffolds were linear enough to encourage cell growth.
Increased linearity is advantageous because nanoscaf-
folds with linear fibers are able to better differentiate
cells and have been used to induce polarity of suscep-
tible cell lines when compared to more loosely based
scaffold systems [24,25].
The cryo-TEM, was performed to measure whether
the cells were properly integrating into the nanoscaffold
meshwork. Electrospinning produces fibers with a high
porosity and interconnected pore structure, a crucial
property that allows cells and nutrients to migrate from
the exterior to the interior of the fibers [26]. We chose
to perform the cryo-TEM as a self-check because, from
our expectations and comparing the growth slope from
Day 2 to Day 4, the significance between Day 4 coated
and non-coated was not as large as expected. We sur-
mised this was due to the increase in average number of
cells on the uncoated nanoscaffold on Day 4, which was
not significantly different from the previous uncoated
control on Day 2 but nonetheless slightly skewed the
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in initial cell seeding would presumably have shown a
significant increase between these two days.
Many biocompatible nanoscaffolds have been used for
in vitro and in vivo repair of various muscle and con-
nective tissues. Here, we developed a PCL nanoscaffold
for use in repair of cardiac muscle. As cardiovascular
issues are the number one killer in the world, the future
for this application is tremendous. Further in vivo stud-
ies will be needed to replicate literature values on the
strength of PCL in the heart, and to insure thymosin β4
can prove to be continually successful.Conclusion
The results obtained in this study suggest that thymosin
β4 is a cardiomyocyte growth factor that, when present,
significantly increases cell growth and proliferation. A
biocompatible and biodegradable nanoscaffold was suc-
cessfully created from a PCL polymer and coated with
an active concentration of Tβ4. This nanoscaffold pro-
vided a support system by which murine-derived cardio-
myocytes were successfully differentiated into functioning
and thriving cardiac tissue. While the regenerative effects
of Tβ4 have been well documented, to our knowledge this
is the first time a platform for Tβ4 utilization had been
fully developed and tested. This successful differentiation
of murine-derived cardiomyocytes treated with Tβ4 on
nanofiber scaffolds may serve as a simple and effective so-
lution to repair various impairments of damaged cardiac
tissue through in vivo implantation.Competing interests
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